News

Virginia Catalyst announces Grant Round 16 awarded projects!

The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16.

“Powerful collaborations between Virginia’s research universities and industry is resulting in major breakthroughs in medical diagnostics, devices, and drug discovery” said Mike Grisham, CEO of Virginia Catalyst. “It’s also generating significant

Through this 16th round of funding, Virginia Catalyst has awarded 65 grants totaling nearly $33 million, resulting in over $50 million in matching funds and over $600 million in follow-on funding to date.

Grant Round 16 awarded projects:

Project:  Readmission Risk Assessment through Physiological and Behavioral Health Monitoring using

VitalStream Wireless Platform

  • Company: Caretaker Medical (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $800,000

Project:  Optimization and Commercialization of PRECYSE as a Novel Quality Control Solution for Next Generation Sequencing

  • Company: Evizia, Inc. (Charlottesville, VA)
  • Funding amount: $800,000
  • University collaborators: Virginia Commonwealth University and University of Virginia

Project:  Developing an exercise-mimetic to treat diabetes

  • Company: MGMedicine, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Tech
  • Funding amount: $780,000

Project:  First-in-Class Bifunctional Cytokine to Target Tissue Resident Tregs for the Treatment of Idiopathic Nephropathy and other Autoimmune Diseases

  • Company: SlateBio, Inc. (Charlottesville, VA)
  • University collaborators: University of Virginia and Virginia Commonwealth University
  • Funding amount: $800,000

 

Recent News

07/19/2024

Capra Biosciences Lands $7.5 Million Project Agreement To Demonstrate Platform To Rapidly Scale Pharmaceutical Ingredient Manufacturing

Many ingredients that make up the pharmaceuticals Americans rely on are manufactured overseas. When supply chain issues or shortages occur, as witnessed during the COVID pandemic, it can negatively impact millions of Americans and affect national security. The White House issued an Executive Order in 2022 to stimulate U.S. biomanufacturing. Increasing American biomanufacturing, will provide

07/15/2024

Lupus Treatment with Omega3-Rich Krill Oil Improves Disease Activity

AMPEL BioSolutions, with collaborators Lupus Therapeutics and Aker Biomarine, revealed peer-reviewed results that supplementation with Omega3-rich Krill Oil improves disease activity of autoimmune Lupus patients. Omega3 lipids called polyunsaturated fatty acids (PUFAs) that are found in microscopic shrimp-like crustaceans called Krill from the waters around Antarctica are key to maintaining a low inflammatory state.  Some

07/15/2024

Inorganic Ventures acquires PURE Analytical Laboratories, Combining Unique Capabilities for Precision Manufacturing

Two privately held specialty chemical firms that provide high-purity materials and services for chemical applications, from renewable energy to food and beverages and consumer safety, are combining their capabilities to serve new and expanding precision markets. IV Labs Inc., the parent company of Inorganic Ventures, has acquired PURE Analytical Laboratories, one of the few companies that